Surveillance for Multisystem Inflammatory Syndrome in US Children Aged 5–11 Years Who Received Pfizer-BioNTech COVID-19 Vaccine, November 2021 through March 2022
| Autor: | Margaret M Cortese, Allan W Taylor, Lara J Akinbami, Andrea Thames-Allen, Anna R Yousaf, Angela P Campbell, Susan A Maloney, Theresa A Harrington, E Gloria Anyalechi, Datta Munshi, Satoshi Kamidani, C Robinette Curtis, David W McCormick, Mary A Staat, Kathryn M Edwards, C Buddy Creech, Oidda Museru, Paige Marquez, Deborah Thompson, John R Su, Elizabeth P Schlaudecker, Karen R Broder |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | The Journal of Infectious Diseases. |
| ISSN: | 1537-6613 0022-1899 |
| Popis: | Multisystem inflammatory syndrome in children (MIS-C) is a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; in the United States, reporting of MIS-C after coronavirus disease 2019 (COVID-19) vaccination is required for vaccine safety monitoring. Pfizer-BioNTech COVID-19 vaccine was authorized for children aged 5−11 years on 29 October 2021. Covering a period when approximately 7 million children received vaccine, surveillance for MIS-C ≤ 90 days postvaccination using passive systems identified 58 children with MIS-C and laboratory evidence of past/recent SARS-CoV-2 infection, and 4 without evidence. During a period with extensive SARS-CoV-2 circulation, MIS-C illness in children after COVID-19 vaccination who lacked evidence of SARS-CoV-2 infection was rare ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|